Neoadjuvant chemotherapy for advanced gastric cancer: A meta-analysis

World Journal of Gastroenterology

Volumn 16, Issue 44, 2010, Pages 5621-5628

  Li, Wei ^a   Qin, Jing ^a   Sun, Yi Hong ^a   Liu, Tian Shu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Gastric cancer; Meta analysis; Neoadjuvant chemotherapy; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; TEGAFUR; URACIL;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; DRUG SAFETY; EMBASE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; LEUKOPENIA; MEDLINE; META ANALYSIS; METASTASIS; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; STOMACH CANCER; SURVIVAL RATE; SYSTEMATIC REVIEW;

EID: 78649715222     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i44.5621     Document Type: Article

References (38)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150
2. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003; 21: 2282-2287
3. Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004; 90: 1727-1732
4. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-- Japan Clinical Oncology Group study 9501. J Clin Oncol 2004; 22: 2767-2773
5. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-1737
6. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820
7. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Achterrath W, Lenaz L, Knipp H. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7: 1318-1326
8. Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002; 183: 274-279
9. Forshaw MJ, Gossage JA, Mason RC. Neoadjuvant chemotherapy for oesophageal cancer: the need for accurate response prediction and evaluation. Surgeon 2005; 3: 373-382, 422
10. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschläger G, Busch R, Siewert JR, Schwaiger M, Fink U. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-3065
11. Takahashi T, Saikawa Y, Yoshida M, Kitagawa Y, Otani Y, Kubota T, Kumai K, Kitajima M. A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer. Anticancer Res 2006; 26: 1631-1635
12. Barone C, Cassano A, Pozzo C, D'Ugo D, Schinzari G, Persiani R, Basso M, Brunetti IM, Longo R, Picciocchi A. Longterm follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer. Oncology 2004; 67: 48-53
13. Persiani R, Rausei S, Pozzo C, Biondi A, Barone C, Cananzi FC, Schinzari G, D'Ugo D. 7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study. Ann Surg Oncol 2008; 15: 2146-2152
14. Kinoshita T, Sasako M, Sano T, Katai H, Furukawa H, Tsuburaya A, Miyashiro I, Kaji M, Ninomiya M. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer 2009; 12: 37-42
15. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M, Howick J. Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009). Available from: URL: http://www.cebm.net/index.aspx?o=1025
16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
17. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.1 (Updated September 2008). The Cochrane Collaboration, 2008. Available from: URL: http://www.cochrane-handbook.org
18. Schuhmacher C, Schlag P, Lordick F, Hohenberger W, Heise J, Haag C, Gretschel S, Mauer ME, Lutz M, Siewert JR. Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. J Clin Oncol (Meeting Abstracts) 2009; 27 (15S): 4510
19. Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T, Bouché O, Segol P, Bedenne L, Rougier P, Ychou M. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD 07-FFCD 9703 trial [Abstract]. Proc Am Soc Clin Oncol 2007; 25 (18S): 4510
20. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20
21. Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der Bijl J, van Krieken JH. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004; 30: 643-649
22. Nio Y, Koike M, Omori H, Hashimoto K, Itakura M, Yano S, Higami T, Maruyama R. A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer--a single institute study. Anticancer Res 2004; 24: 1879-1887
23. Zhang CW, Zou SC, Shi D, Zhao DJ. Clinical significance of preoperative regional intra-arterial infusion chemotherapy for advanced gastric cancer. World J Gastroenterol 2004; 10: 3070-3072
24. Kobayashi T, Kimura T. [Long-term outcome of preoperative chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR) for gastric cancer] Gan To Kagaku Ryoho 2000; 27: 1521-1526
25. Wang XL, Wu GX, Zhang MD, Guo M, Zhang H, Sun XF. A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncol Rep 2000; 7: 241-244
26. Takiguchi N, Oda K, Suzuki H, Wakatsuki K, Nunomora M, Kouda K, Saito N, Nakajima N. Neoadjuvant chemotherapy with 5-fluorouracil (5-FU) or low dose cis-platinum (CDDP) + 5-FU in the treatment of gastric carcinoma with serosal invasion. Proc Am Soc Clin Oncol 2000; 19: A1178
27. Lygidakis NJ, Sgourakis G, Aphinives P. Upper abdominal stop-flow perfusion as a neo and adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective randomized clinical trial. Hepatogastroenterology 1999; 46: 2035-2038
28. Kang YK, Choi DW, Im YH, Kim CM, Lee JI, Moon NM, Lee JO. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. Abstract 503 presented at the ASCO Annual Meeting, 1996. Available from: URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=29&abstractID=10042
29. Masuyama M, Taniguchi H, Takeuchi K, Miyata K, Koyama H, Tanaka H, Higashida T, Koishi Y, Mugitani T, Yamaguchi T. [Recurrence and survival rate of advanced gastric cancer after preoperative EAP-II intra-arterial infusion therapy] Gan To Kagaku Ryoho 1994; 21: 2253-2255
30. Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S, Ohoyama S, Takashima T, Kimura H, Kamata T. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993; 17: 256-261; discussion 261-262
31. Nishioka B, Ouchi T, Watanabe S, Umehara M, Yamane E, Yahata K, Muto F, Kojima O, Nomiyama S, Sakita M, Fujita Y, Majima S. [Follow-up study of preoperative oral administration of an antineoplastic agent as an adjuvant chemotherapy in stomach cancer] Gan To Kagaku Ryoho 1982; 9: 1427-1432
32. Liu TS, Wang Y, Chen SY, Sun YH. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol 2008; 34: 1208-1216
33. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997
34. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46
35. Untch M, von Minckwitz G. Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res 2009; 11: 203
36. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22: 2069-2077
37. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730
38. Satoh S. S-1 and cisplatin in treating patients who are undergoing surgery for stage III stomach cancer, Available from: URL: http://clinicaltrials.gov/show/NCT00182611